| Literature DB >> 32972048 |
Hui Sun1,2, Qing Chang1,2, Ya-Shu Liu1,2, Yu-Ting Jiang1,2, Ting-Ting Gong3, Xiao-Xin Ma3, Yu-Hong Zhao1,2, Qi-Jun Wu1,2.
Abstract
PURPOSE: The evidence of adherence to cancer prevention guidelines and endometrial cancer (EC) risk has been limited and controversial. This study summarizes and quantifies the relationship between adherence to cancer prevention guidelines and EC risk.Entities:
Keywords: Cancer prevention guidelines; Endometrial neoplasms; Prospective study; Risk; Systematic review
Mesh:
Year: 2020 PMID: 32972048 PMCID: PMC7811997 DOI: 10.4143/crt.2020.546
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 4.679
Fig. 1Flowchart for the selection of the original studies on the association between adherence to cancer prevention guidelines score and the endometrial cancer risk included in the meta-analysis.
Characteristics of studies included in the meta-analysis
| Study | Age range (yr) | Menopausal status | Sample size | No. of cases | Duration of follow-up (yr) | Exposure | Assessment of endometrial cancer | Score | HR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Romaguera et al. (2012) [ | 25–70 | Total | 260,098 | 1,148 | 11.0 | WCRF/AICR score | Medical record | ≥ 0 to ≤ 3 | 1.00 (reference) |
| > 3 to < 4 | 0.88 (0.75–1.04) | ||||||||
| ≥ 4 to < 5 | 0.79 (0.68–0.93) | ||||||||
| ≥ 5 to ≤ 7 | 0.77 (0.62–0.94) | ||||||||
|
| |||||||||
| Dartois et al. (2014) [ | 43–68 | Total | 64,732 | 270 | 15.0 | Health index | Self-reported and medical record | ≥ 0 to ≤ 2 | 1.00 (reference) |
| ≥ 2.5 to ≤ 3 | 0.61 (0.39–0.97) | ||||||||
| ≥ 3.5 to ≤ 4 | 0.48 (0.31–0.73) | ||||||||
| ≥ 4.5 to ≤ 5 | 0.45 (0.29–0.71) | ||||||||
|
| |||||||||
| Kabat et al. (2015) [ | 50–71 | Total | 189,575 | 1,518 | 10.5 | ACS score | Medical record | ≥ 0 to ≤ 3 | 1.00 (reference) |
| ≥ 4 to ≤ 5 | 0.71 (0.61–0.83) | ||||||||
| 6 | 0.62 (0.52–0.73) | ||||||||
| 7 | 0.48 (0.40–0.57) | ||||||||
| ≥ 8 to ≤ 11 | 0.40 (0.34–0.46) | ||||||||
|
| |||||||||
| Arthur et al. (2018) [ | 47–70 | Total | 2,519 | 177 | 11.0 | Healthy lifestyle index score | Medical record | ≥ 0 to ≤ 10 | 1.00 (reference) |
| ≥ 11 to ≤ 12 | 0.85 (0.51–1.41) | ||||||||
| ≥ 13 to ≤ 14 | 0.52 (0.41–0.98) | ||||||||
| ≥ 15 to ≤ 20 | 0.52 (0.28–0.99) | ||||||||
|
| |||||||||
| Arthur et al. (2019) [ | 50–79 | Post | 80,123 | 1,357 | 17.9 | Healthy lifestyle index score | Medical record | ≥ 0 to ≤ 10 | 1.00 (reference) |
| ≥ 11 to ≤ 12 | 0.70 (0.60–0.82) | ||||||||
| 13 | 0.79 (0.66–0.95) | ||||||||
| ≥ 14 to ≤ 15 | 0.65 (0.55–0.76) | ||||||||
| ≥ 16 to ≤ 20 | 0.61 (0.51–0.72) | ||||||||
ACS, the American Cancer Society, including diet, physical activity, body mass index, and alcohol consumption; CI, confidence interval; HR, hazard ratio; WCRF/AICR, the World Cancer Research Fund and the American Institute of Cancer Research, including body fatness, physical activity, consumption of foods and drinks that promote weight gain, consumption of plant foods, consumption of animal foods, consumption of alcoholic drinks, and breastfeeding in women.
Including smoking, body mass index, alcohol consumption, fruit and vegetable consumption, and physical activity,
Including diet, smoking, alcohol consumption, physical activity, and body mass index.
Quality assessment scores according to the Newcastle-Ottawa Scale
| Study | Selection | Comparability | Outcome | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
| ||||||
| Representativeness of the exposed cohort | Selection of unexposed cohort | Ascertainment of exposure | Outcome of interest not present at start of study | Control for important factor or additional factor | Assessment of outcome | Follow-up long enough for outcomes to occur | Adequacy of follow-up of cohorts | |
| Romaguera et al. [ | - | |||||||
|
| ||||||||
| Dartois et al. [ | - | - | - | |||||
|
| ||||||||
| Kabat et al. [ | - | |||||||
|
| ||||||||
| Arthur et al. [ | - | |||||||
|
| ||||||||
| Arthur et al. [ | - | |||||||
A study could be awarded a maximum of one star for each item except for the item control for important factor or additional factor. The definition/explanation of each column of the Newcastle-Ottawa Scale is available from (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
A maximum of 2 stars could be awarded for this item. Studies that controlled for use of menopausal hormone therapy, age at first menarche received one star, whereas studies that controlled for other important confounders such as level of education received an additional star,
A cohort study with a median follow-up time ≥ 10 years was assigned one star,
A cohort study with a follow-up rate > 75% was assigned one star.
One asterisk represents a condition that meets the evaluation criteria,
The two asterisks represent two conditions that meet the evaluation criteria.
Confounders and adjustment methods of studies included in the meta-analysis
| Study | Confounders | Adjustment methods |
|---|---|---|
| Romaguera et al. (2012) [ | Energy intake, level of education, smoking status, intensity of smoking, presence of chronic diseases at baseline, ever use of contraceptive pills, ever use of hormone replacement therapy, age at first menarche, age at first pregnancy, menopausal status | Cox regression model |
| Dartois et al. (2014) [ | Level of education, residence, first-degree family history of any cancer, professional activity, use of oral contraceptives, age at menarche and number of children, age at first full-term pregnancy, menopausal status, use of menopausal hormone therapy | Cox proportional hazards regression models |
| Kabat et al. (2015) [ | Age, educational level, ethnicity, smoking status, marital status, energy intake, menopausal status, age at menarche, age at first birth, parity, hormone therapy use | Cox proportional hazards models |
| Arthur et al. (2018) [ | Education, non-alcohol energy intake, smoking status, alcohol intake, BMI, history of oophorectomy, diet score, physical activity, age at menarche, parity, menopause, HRT use, oral contraceptive use, family history of breast cancer | Cox regression models |
| Arthur et al. (2019) [ | Age at entry, education, non-alcohol energy intake, ethnicity, age at menarche, parity, combined estrogen and progesterone therapy, unopposed estrogen therapy, oral contraceptive use, family history of endometrial cancer, age at menopause | Cox proportional hazards models |
BMI, body mass index; HRT, hormone replacement therapy.
Fig. 2Forest plot for the association between adherence to cancer prevention guidelines score and the endometrial cancer risk using a random-effects model [12–14,16,17]. The squares indicate study-specific hazard ratio (size of the square reflects the study-specific statistical weight); the horizontal lines indicate 95% confidence intervals (CIs); and the diamond indicates the summary hazard ratio (HR) estimate with its 95% CI.
Fig. 3Funnel plot with pseudo 95% confidence limits for the analysis of adherence to cancer prevention guidelines score and the endometrial cancer risk. HR, hazard ratio.
Fig. 4Sensitivity analysis was performed by removing each study in turn and recalculating the summary hazard ratios estimate [12–14,16,17].
Fig. 5Forest plot for the association between adherence to cancer prevention guidelines score and the endometrial cancer risk using a random-effects model in sensitivity analysis [13–17]. The squares indicate study-specific hazard ratio (size of the square reflects the study-specific statistical weight); the horizontal lines indicate 95% confidence intervals (CIs); and the diamond indicates the summary hazard ratio (HR) estimate with its 95% CI.
Fig. 6Forest plot for the dose-response meta-analysis of the relationship between adherence to cancer prevention guidelines scores and the endometrial cancer risk using a random-effects model [12,13,17]. The squares indicate study-specific hazard ratio (HR) (size of the square reflects the study-specific statistical weight); the horizontal lines indicate 95% confidence intervals (CIs); and the diamond indicates the summary HR estimate with its 95% CI.